Middle East and Africa Hunter Syndrome Treatment Market, BySeverity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Middle East and Africa Hunter Syndrome Treatment Market
Middle East & Africa hunter syndrome treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.0% in the forecast period of 2021 to 2028 and is expected to reach USD 22.55 million by 2028. Increasing government support for healthcare and rising awareness regarding current and novel hunter syndrome treatment products are the major drivers which propelled the demand of the market in the forecast period.
Hunter syndrome is a rare, inherited genetic disorder caused by missing or malfunctioning of enzyme, iduronate-2-sulfatase. Due to which body doesn’t properly digest or break down sugar molecules in the body. When these molecules build up in organs and tissues over time, they can cause damage that affects physical and mental development and abilities. The disorder almost always occurs in boys. The condition is one type of a group of inherited metabolic disorders called mucopolysaccharidosis (MPS).
Hunter syndrome is a rare, inherited disorder in which the body does not properly digest (break down) sugar molecules in the body. When these molecules build up in organs and tissues over time, they can cause damage that affects physical and mental development and abilities.
Public awareness about the syndrome and treatment options, improving healthcare infrastructure and increasing investment by the government for the growth of the healthcare industry across the globe is likely to accelerate the growth of the Middle East and Africa hunter syndrome treatment market in the forecast period. On the other hand, favourable government initiatives and technological advancements will further bring immense opportunities for the growth of the hunter syndrome treatment market in the above mentioned forecast period. However, adverse effects related to the treatment, lack of etiology, and low prevalence rate are factors expected to restraint the market growth in the forecast period.
The hunter syndrome treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Hunter Syndrome Treatment Market Scope and Market Size
Hunter syndrome treatment market is segmented on the basis of severity, types, complications, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of severity, the Middle East and Africa hunter syndrome treatment market is segmented into mild to moderate and moderate to severe. In 2021, the moderate to severe segment is dominating the Middle East and Africa hunter syndrome treatment market due to increase in the cases of prevalence rate of genetic inherited disorders among population of Middle East and Africa.
- On the basis of type, the Middle East and Africa hunter syndrome treatment market is segmented into enzyme replacement therapy (ERT), stem cell transplant, surgical treatment and others. In 2021, enzyme replacement therapy (ERT) is dominating the Middle East and Africa hunter syndrome treatment market as it don’t alter the course of neurological decline, but may produce somatic improvements.
- On the basis of complications, the Middle East and Africa hunter syndrome treatment market is segmented into respiratory disorders, neurological disorders, gastrointestinal disorders, cardiovascular, ophthalmic, audiologic, dental, musculoskeletal, others. In 2021, the respiratory disorders segment is dominating the Middle East and Africa hunter syndrome treatment market due to due to increasing R&D investments by key market players in the market.
- On the basis of end user, the Middle East and Africa hunter syndrome treatment market is segmented into hospitals, clinics, home healthcare and others. In 2021, the hospitals segment is dominating the Middle East and Africa hunter syndrome treatment market due to improved processes, and facility management available at hospital.
- On the basis of distribution channel, the Middle East and Africa hunter syndrome treatment market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the Middle East and Africa hunter syndrome treatment market due to increased interaction with prescribers and other health professionals.
Hunter Syndrome Treatment Market Country Level Analysis
The hunter syndrome treatment market is analyzed and market size information is provided on the basis of severity, types, complications, end user and distribution channel.
The countries covered in the hunter syndrome treatment market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.
Hospital pharmacy segment.in Middle East and Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of robust pipelines for development of newer treatment and the growth in awareness regarding the disorder.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
The Increase in the Cases of Inherited Genetic Disorders among Population across the Globe and Favorable Government Initiatives are Boosting the Market Growth of Hunter Syndrome Treatment Products
Hunter syndrome treatment market also provides you with detailed market analysis for every country growth in hunter syndrome treatment products industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the hunter syndrome treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Hunter Syndrome Treatment Market Share Analysis
Hunter syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to hunter syndrome treatment market.
The major companies operating in the Middle East and Africa hunter syndrome treatment are Takeda Pharmaceutical Company Limited, Medtronic, Abbott, BD, Stryker, Novartis AG, and Pfizer Inc., Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the hunter syndrome treatment market.
For instance,
- In March 2021, Children’s National Hospital and Takeda Pharmaceutical Company Limited announced the creation of the Rare Disease Clinical Activity Protocols (Rare-CAP) program, which will establish a networked system for the development, dissemination and curation of protocols to help standardize the process of diagnosis and care for patients with rare diseases. This partnership underscores companies’ commitment in driving continuous innovation and personalized care for patients with rare diseases.
- In January 2021, Pfizer Inc. announced that during the second half of 2020, it invested a total of USD 120.00 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Pfizer is investing a huge amount of around USD 500.00 million in various biotechnology companies. This investment will help the Pfizer to ensure the continuity of promising clinical development programs for future strategic interest. It had helped the company to expand its business by entering and innovating new products.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the hunter syndrome treatment market which also provides the benefit for organization to improve their offering for hunter syndrome treatment drugs.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EMERGING TREATMENTS FOR HUNTER SYNDROME
5.1 TREATMENT: DNL310
5.2 TREATMENT: JR141
5.3 TREATMENT: TAK-609/SHP609/HGT-2310
5.4 TREATMENT: RGX-121
5.5 TREATMENT: SB-913
5.6 TREATMENT: AVR-RD-05
5.7 TREATMENT: ODIPARCIL
5.8 TREATMENT: AGT-181
5.9 TREATMENT: EGT-301
6 REGULATORY GUIDELINES FOR HUNTER SYNDROME (MPS II)
6.1 U.S REGULATORY FRAMEWORK FOR HUNTER SYNDROME
6.2 EUROPE REGULATORY FRAMEWORK FOR HUNTER SYNDROME
6.3 ASIA-PACIFIC REGULATORY FRAMEWORK FOR HUNTER SYNDROME
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF HUNTER SYNDROME
8.1.2 RISING ADOPTION OF GENE THERAPY
8.1.3 INCREASING GOVERNMENT INITIATIVES
8.1.4 INCREASING FUND BY PUBLIC AND PRIVATE ORGANISATIONS
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 ADVERSE EFFECTS OF CURRENT TREATMENTS
8.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MPS II TREATMENT DEVELOPMENT
8.2.3 UNAWARENESS AMONG PEOPLE OF THE EXISTENCE OF HUNTER SYNDROME
8.2.4 HIGH COST ASSOCIATED WITH TREATMENT OF MPS II
8.3 OPPORTUNITIES
8.3.1 HIGH DEMAND OF DISEASE-SPECIFIC TREATMENT
8.3.2 RISING COLLABORATIONS, AND MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS
8.3.3 PRESENCE OF NOVEL PIPELINE DRUGS
8.4 CHALLENGES
8.4.1 LIMITATIONS OF CURRENT TREATMENT
8.5 IMPROPER REIMBURSEMENT POLICIES
9 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY
10.1 OVERVIEW
10.2 MODERATE TO SEVERE
10.3 MILD TO MODERATE
11 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 ENZYME REPLACEMENT THERAPY
11.2.1 ELAPRASE + TAK-609
11.2.2 HUNTERASE
11.2.3 IZCARGO
11.3 STEM CELL TRANSPLANT
11.3.1 UMBILICAL CORD TRANSPLANT
11.3.2 BONE MARROW TRANSPLANT
11.4 SURGICAL TREATMENT
11.4.1 CARDIAC VALVE REPLACEMENT SURGERY
11.4.2 TRACHEOSTOMY
11.4.3 POSITIVE AIRWAY PRESSURE DEVICES
11.4.4 JOINT CONTRACTURES
11.4.5 ABDOMINAL HERNIA SURGERY
11.4.6 OTHERS
11.5 OTHERS
12 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS
12.1 OVERVIEW
12.2 RESPIRATORY DISORDERS
12.3 NEUROLOGICAL DISORDERS
12.4 CARDIOVASCULAR
12.5 MUSCULOSKELETAL
12.6 GASTROINTESTINAL DISORDERS
12.7 OPHTHALMIC
12.8 AUDIOLOGIC
12.9 DENTAL
12.1 OTHERS
13 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
14.5 OTHERS
15 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY REGION
15.1 MIDDLE EAST & AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E.
15.1.4 EGYPT
15.1.5 ISRAEL
15.1.6 KUWAIT
15.1.7 REST OF MIDDLE EAST & AFRICA
16 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 GREEN CROSS CORP.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 ABBOTT
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENTS
18.4 AVROBIO, INC.
18.4.1 COMPANY SNAPSHOT
18.4.2 PRODUCT PORTFOLIO
18.4.3 RECENT DEVELOPMENTS
18.5 BD
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 CANBRIDGE LIFE SCIENCES LTD.
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 DENALI THERAPEUTICS
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 HOMOLOGY MEDICINES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 TECHNOLOGY PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 INVENTIVA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 JASPER THERAPEUTICS, INC.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 JCR PHARMACEUTICALS CO., LTD.
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 JOHNSON & JOHNSONS SERVICES, INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 MEDTRONIC
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 NOVARTIS AG
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENTS
18.15 ON-X LIFE TECHNOLOGIES (A SUBSIDIARY OF CRYOLIFE, INC.)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 PFIZER INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 REGENXBIO INC.
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 SANGAMO THERAPEUTICS
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 STRYKER
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENTS
18.2 UCB S.A.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA MODERATE TO SEVERE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA MILD TO MODERATE IN MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA RESPIRATORY DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA CARDIOVASCULAR IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA MUSCULOSKELETAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA OPHTHALMIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA AUDIOLOGIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA DENTAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
TABLE 23 MIDDLE EAST AND AFRICA HOSPITALS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA CLINICS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
TABLE 28 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN HUNTER SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 41 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 42 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 43 SOUTH AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 44 SOUTH AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 45 SOUTH AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 46 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 47 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 48 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 50 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 SAUDI ARABIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 SAUDI ARABIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 SAUDI ARABIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 55 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 U.A.E. ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 U.A.E. STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 U.A.E. SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 63 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 66 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 EGYPT ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 EGYPT STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 EGYPT SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 71 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 72 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 73 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 74 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 ISRAEL ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 ISRAEL STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 ISRAEL SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 79 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 82 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 KUWAIT ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 KUWAIT STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 KUWAIT SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
TABLE 87 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 88 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 89 REST OF MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
List of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALANCE OF HUNTER SYNDROME IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 MODERATE TO SEVERE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR HUNTER SYNDROME TREATMENT PRODUCT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET
FIGURE 16 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY, 2020
FIGURE 19 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
FIGURE 20 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 21 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 22 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 23 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 24 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 25 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
